ReviewCancer cell international2021

Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis.

Ziqi Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.